Remove 2014 Remove Communication Remove Pharmaceutical Companies
article thumbnail

The 20 Key Moments in the 340B Program's 30-Year History

Omnicell

There was bipartisan support for the program at the hearing and support for measures such as requiring pharmaceutical companies to publish their prices in a password protected site on HRSA's website. Four of the five staffers originally involved in the investigation now work for or lobby for the pharmaceutical industry.

article thumbnail

What a mild recession could mean for small biotechs in 2023

Pharmaceutical Technology

This economic change impacts employment, income, industrial production, and more, and the pharmaceutical industry will not be exempt. While larger, more established pharmaceutical companies may have the infrastructure and financial cushion to fall back on, SMEs need to tread carefully through these economic challenges.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

ISPE Briefs: A Comprehensive Reference for Continuous Manufacturing of OSD

ISPE

The ISPE OSD Community of Practice formed a working team in 2017 to advance the use of continuous manufacturing in the pharmaceutical industry and to increase the long-term efficiency and affordability of the manufacture of OSD products. Meet Heather Patterson, Human Resources Manager.

Dosage 52
article thumbnail

Pliant snags $287.5 million in oversubscribed public offering amid market uncertainty

Pharmaceutical Technology

The FDA approved both drugs in 2014. In an email , a Pliant spokesperson told Pharmaceutical Technology , “As currently approved therapies are not well tolerated, a new agent with a favorable safety profile and demonstrated efficacy would be a welcome addition to the IPF treatment armamentarium”.

FDA 59
article thumbnail

Zepbound alternatives: What can I take instead of Zepbound?

The Checkup by Singlecare

It wasn’t until 2014 when a GLP-1 first received FDA approval for weight loss—Saxenda (liraglutide). Communication between patient and healthcare provider is critical during transition periods to assess side effects, ability to increase dose, and potential drug interactions with the alternative.

FDA 52
article thumbnail

Why pharma needs a revolution in culture

pharmaphorum

James Dempsey breaks down the misconception that culture can’t be measured, and gives tips for how companies can implement a clear culture strategy. As the sector looks to maintain its momentum, it must be wary that positive messaging and increased scrutiny does not end up as a recipe for a hard fall.

article thumbnail

Removing Regulatory Hurdles for Continuous Pharmaceutical Manufacturing

ISPE

For example, one pharmaceutical company that switched to CM reported a 50% reduction in operating costs, a 33% reduction in waste, an 80% reduction in manufacturing and testing cycle time, and a 66% reduction in time from testing to release. 5 In addition, there are human elements to consider.

FDA 52